Broad Effectiveness: Study With Aripiprazole - Tabular View

Home

Broad Effectiveness: Study With Aripiprazole

This study has been completed.

Study NCT00036361. Last updated on June 27, 2008. Information provided by Bristol-Myers Squibb

This Tabular View shows the required WHO registration data elements as marked by ^†

Descriptive Information Fields
Brief Title ^†	Broad Effectiveness: Study With Aripiprazole
Official Title ^†	Broad Effectiveness: Study With Aripiprazole
Brief Summary	The purpose of this study is to learn if aripiprazole is effective in the treatment of a large number of persons diagnosed with schizophrenia or schizoaffective disorders
Detailed Description
Study Phase	Phase III
Study Type ^†	Interventional
Study Design ^†	Treatment, Non-Randomized, Open Label, Active Control, Parallel Assignment, Safety Study
Primary Outcome Measure ^†	Safety Assessments
Secondary Outcome Measure ^†	Safety Assessments
Condition ^†	Schizophrenia Schizoaffective Disorder
Intervention ^†	Drug: Aripiprazole
MEDLINE PMIDs
Links	BMS Clinical Trials Disclosure For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm

Recruitment Information Fields
Recruitment Status ^†	Completed
Enrollment ^†	444
Start Date ^†	July 2002
Completion Date
Eligibility Criteria ^†	Patients with Schizophrenia or Schizoaffective Disorder
Gender	Both
Ages	18 Years to 75 Years
Accepts Healthy Volunteers	No
Contacts ^††
Location Countries ^†	United States

Administrative Information Fields
NCT ID ^†	NCT00036361
Organization ID	CN138-087
Secondary IDs ^††
Study Sponsor ^†	Bristol-Myers Squibb
Collaborators ^††	Otsuka America Pharmaceutical
Investigators ^†
Information Provided By	Bristol-Myers Squibb
Verification Date	September 2007
First Received Date ^†	May 8, 2002
Last Updated Date	June 27, 2008

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.